Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy.
Department of Biology & Biochemistry, University of Bath, Bath, BA2-7AX, UK.
Invest New Drugs. 2021 Jun;39(3):879-890. doi: 10.1007/s10637-021-01068-8. Epub 2021 Jan 21.
Non-small cell lung cancer (NSCLC) is one of the most frequent causes of mortality in the western world. v-raf murine sarcoma viral oncogene homolog B (BRAF) is a member of the Raf kinase family and plays a critical role in cellular growth, proliferation, and differentiation through the mitogen-activated protein kinase pathway. The incidence of BRAF mutations in NSCLC is low, accounting for 0-3% of all cases of lung cancer. Given the results obtained in metastatic melanoma, several studies have reported the efficacy of anti-BRAF therapies in NSCLC treatment. In this review, we describe changes in the landscape of BRAF-mutated lung cancer treatment and analyze insights from major clinical trials in the context of future therapeutic prospects.
非小细胞肺癌（NSCLC）是西方世界最常见的死亡原因之一。v-raf 鼠肉瘤病毒癌基因同源物 B（BRAF）是 Raf 激酶家族的成员，通过丝裂原活化蛋白激酶途径在细胞生长、增殖和分化中发挥关键作用。BRAF 突变在 NSCLC 中的发生率较低，占所有肺癌病例的 0-3%。鉴于转移性黑色素瘤的研究结果，几项研究报告了抗 BRAF 治疗在 NSCLC 治疗中的疗效。在这篇综述中，我们描述了 BRAF 突变型肺癌治疗领域的变化，并分析了主要临床试验的结果，探讨了未来的治疗前景。
